Pegylated liposomal doxorubicin (PLD) with bevacizumab (B) in second-line treatment of ovarian cancer (OC): Pharmacokinetics (PK), safety, and preliminary outcome results

被引：0
|
作者：
Muggia, F. M. [1 ,2 ]
Boyd, L. [1 ,2 ]
Liebes, L. [1 ,2 ]
Downey, A. [1 ,2 ]
Muller, C. [1 ,2 ]
Pothuri, B. [1 ,2 ]
Blank, S. [1 ,2 ]
Rutledge, T. [1 ,2 ]
Fishman, D. [1 ,2 ]
Verschraegen, C. [1 ,2 ]
机构：
[1] NYU, Sch Med, New York, NY USA
[2] Univ New Mexico, Albuquerque, NM 87131 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5548
引用
收藏
页数：2
相关论文
共 50 条
  • [11] Pegylated liposomal doxorubicin for first-line treatment of epithelial ovarian cancer
    Lawrie, Theresa A.
    Rabbie, Roy
    Thoma, Clemens
    Morrison, Jo
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2013, (10):
  • [12] Cellular function of the mononuclear phagocyte system (MPS) as a phenotypic probe for pegylated liposomal doxorubicin (PLD) pharmacokinetics (PK) in patients with recurrent ovarian cancer.
    Caron, W. P.
    Lay, J. C.
    Fong, A. M.
    La-Beck, N. M.
    Newman, S. E.
    Clarke-Pearson, D. L.
    Brewster, W. R.
    Van Le, L.
    Bae-Jump, V. L.
    Gehrig, P. A.
    Zamboni, W.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [13] Clinical phase II study of pegylated liposomal doxorubicin as second-line treatment in disseminated melanoma
    Fink, W
    Zimpfer-Rechner, C
    Thoelke, A
    Figl, R
    Kaatz, M
    Ugurel, S
    Schadendorf, D
    ONKOLOGIE, 2004, 27 (06): : 540 - 544
  • [14] A randomized phase III study of gemcitabine (GEM) versus pegylated liposomal doxorubicin (PLD) in progressive/recurrent ovarian cancer (OC)
    Ferrandina, G.
    Lorusso, D.
    Pignata, S.
    Breda, E.
    Savarese, A.
    Nardi, M.
    Scaltriti, L.
    Ludovisi, M.
    Scambia, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [15] Pegylated liposomal doxorubicin (PLD) treatment for recurrent epithelial ovarian cancer (rEOC): Implications of BRCA mutations
    Safra, T.
    Borgato, L.
    Nicoletto, M.
    Rolnitzky, L.
    Curtin, J.
    Geva, R.
    Peles, S.
    Grenader, T.
    Gabizon, A.
    Muggia, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [16] Relationship Between Complement Factors and CC Chemokines and the Pharmacokinetics (PK) and Pharmacodynamics (PD) of PEGylated Liposomal Doxorubicin (PLD) in Patients with Refractory Epithelial Ovarian Cancer (EOC)
    Song, G.
    Moore, S.
    Tarrant, T.
    Dobrovolskaia, M.
    Barrow, D.
    Kumar, P.
    Newman, S.
    Bae-Jump, V.
    Gehrig, P.
    Zamboni, W.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 39 - 40
  • [17] Pegylated liposomal doxorubicin (PLD) and gemcitabine (GEM) in combination in the salvage treatment of epithelial ovarian cancer (OC) - a Danish Gynaecologic Cancer Group (DGC) study.
    Mirza, M. R.
    Lund, B.
    Bertelsen, K.
    Lindegaard, J.
    Keldsen, N.
    Mellemgaard, A.
    Depont, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 279S - 279S
  • [18] Final survival results of the randomized phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer
    Monk, B. J.
    Herzog, T. J.
    Kaye, S. B.
    Krasner, C. N.
    Vermorken, J. B.
    Muggia, F.
    Pujade-Lourraine, E.
    Zintl, P.
    Parekh, T. V.
    Poveda, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [19] Response to pegylated liposomal doxorubicin (PLD) and weekly paclitaxel (wpac) in platinum resistant (PR) ovarian cancer (OC) by BRCA mutation status
    Bremer, L. C.
    Pate, C. L.
    Banerjee, S.
    George, A.
    ANNALS OF ONCOLOGY, 2019, 30 : 420 - 420
  • [20] A phase I/II study of maplirpacept in combination with pegylated liposomal doxorubicin (PLD) in patients with platinum-resistant ovarian cancer (OC): Phase 1 results
    Street, Daron G.
    Kuttschreuter, Luke
    Starks, David
    Mahdi, Haider
    Linn, Carlos
    Pavlov, Dmitri
    Peguero, Julio Antonio
    Chawla, Sant P.
    Bruns, Ingmar
    Waggoner, Steven E.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345